pantoprazole has been researched along with Critical Illness in 16 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This suggests that for stress ulcer prophylaxis, intermittent dosing with an intravenous proton pump inhibitor may be an alternative to high-dose continuous infusions of a histamine-2-receptor antagonist." | 2.41 | Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. ( Steinberg, KP, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dennis, BB | 1 |
| Thabane, L | 3 |
| Heels-Ansdell, D | 2 |
| Dionne, JC | 1 |
| Binnie, A | 1 |
| Tsang, J | 1 |
| Guyatt, G | 3 |
| Ahmed, A | 1 |
| Lauzier, F | 3 |
| Deane, A | 2 |
| Arabi, Y | 2 |
| Marshall, J | 2 |
| Zytaruk, N | 3 |
| Saunders, L | 2 |
| Finfer, S | 3 |
| Myburgh, J | 2 |
| Muscedere, J | 3 |
| English, S | 2 |
| Ostermann, M | 2 |
| Hardie, M | 2 |
| Knowles, S | 2 |
| Cook, D | 3 |
| Billot, L | 1 |
| Alhazzani, W | 2 |
| Young, P | 1 |
| Venkatesh, B | 1 |
| Hammond, N | 1 |
| Poole, A | 1 |
| Al-Fares, A | 1 |
| Xie, F | 1 |
| Hall, R | 2 |
| Gündoğan, K | 1 |
| Karakoc, E | 1 |
| Teke, T | 1 |
| Zerman, A | 1 |
| Esmaoglu, A | 1 |
| Temel, Ş | 1 |
| Güven, M | 1 |
| Sungur, M | 1 |
| Callaway, K | 1 |
| Lakkad, M | 1 |
| Painter, JT | 1 |
| Dayer, L | 1 |
| Oswalt, AK | 1 |
| Foroutan, N | 1 |
| Fahimi, F | 1 |
| Dabiri, Y | 1 |
| Foroutan, A | 1 |
| Habibi, M | 1 |
| Salamzadeh, J | 1 |
| Alshahrani, M | 1 |
| Deane, AM | 1 |
| Marshall, JC | 1 |
| English, SW | 1 |
| Arabi, YM | 1 |
| Karachi, T | 1 |
| Rochwerg, B | 1 |
| Daneman, N | 1 |
| Alshamsi, F | 1 |
| Heel-Ansdell, D | 1 |
| Krag, M | 4 |
| Perner, A | 3 |
| Wetterslev, J | 3 |
| Lange, T | 3 |
| Wise, MP | 3 |
| Borthwick, M | 3 |
| Bendel, S | 3 |
| Pelosi, P | 1 |
| Keus, F | 3 |
| Guttormsen, AB | 3 |
| Schefold, JC | 3 |
| Meyhoff, TS | 2 |
| Marker, S | 3 |
| Møller, MH | 4 |
| El-Kersh, K | 1 |
| Jalil, B | 1 |
| McClave, SA | 1 |
| Cavallazzi, R | 1 |
| Guardiola, J | 1 |
| Guilkey, K | 1 |
| Persaud, AK | 1 |
| Furmanek, SP | 1 |
| Guinn, BE | 1 |
| Wiemken, TL | 1 |
| Alhariri, BC | 1 |
| Kellie, SP | 1 |
| Saad, M | 1 |
| Schoergenhofer, C | 1 |
| Hobl, EL | 1 |
| Schellongowski, P | 1 |
| Heinz, G | 1 |
| Speidl, WS | 1 |
| Siller-Matula, JM | 1 |
| Schmid, M | 1 |
| Sunder-Plaßmann, R | 1 |
| Stimpfl, T | 1 |
| Hackl, M | 1 |
| Jilma, B | 1 |
| Rasmussen, BS | 1 |
| Siegemund, M | 1 |
| Bundgaard, H | 1 |
| Elkmann, T | 1 |
| Jensen, JV | 1 |
| Nielsen, RD | 1 |
| Liboriussen, L | 1 |
| Bestle, MH | 1 |
| Elkjær, JM | 1 |
| Palmqvist, DF | 1 |
| Bäcklund, M | 1 |
| Laake, JH | 1 |
| Bådstøløkken, PM | 1 |
| Grönlund, J | 1 |
| Breum, O | 1 |
| Walli, A | 1 |
| Winding, R | 1 |
| Iversen, S | 1 |
| Jarnvig, IL | 1 |
| White, JO | 1 |
| Brand, B | 1 |
| Madsen, MB | 1 |
| Quist, L | 1 |
| Thornberg, KJ | 1 |
| Møller, A | 1 |
| Wiis, J | 1 |
| Granholm, A | 1 |
| Anthon, CT | 1 |
| Hjortrup, PB | 1 |
| Aagaard, SR | 1 |
| Andreasen, JB | 1 |
| Sørensen, CA | 1 |
| Haure, P | 1 |
| Hauge, J | 1 |
| Hollinger, A | 1 |
| Scheuzger, J | 1 |
| Tuchscherer, D | 1 |
| Vuilliomenet, T | 1 |
| Takala, J | 1 |
| Jakob, SM | 1 |
| Vang, ML | 1 |
| Pælestik, KB | 1 |
| Andersen, KLD | 1 |
| van der Horst, ICC | 1 |
| Dieperink, W | 1 |
| Fjølner, J | 1 |
| Kjer, CKW | 1 |
| Sølling, C | 1 |
| Sølling, CG | 1 |
| Karttunen, J | 1 |
| Morgan, MPG | 1 |
| Sjøbø, B | 1 |
| Engstrøm, J | 1 |
| Agerholm-Larsen, B | 1 |
| Lwin, AA | 1 |
| Gursoy, O | 1 |
| Memiş, D | 1 |
| Sut, N | 1 |
| Tsai, JJ | 1 |
| Lin, HJ | 1 |
| Steinberg, KP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients Pilot Trial[NCT03372707] | 100 participants (Actual) | Interventional | 2018-07-05 | Completed | |||
| Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)[NCT02467621] | Phase 4 | 3,350 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Laparoscopic Revision Gastric Bypass Surgery for Perforated Marginal Ulcer: A 10 Year Experience[NCT01041196] | 30 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Data for landmark mortality 1 year after randomization. (NCT02467621)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 610 |
| Normal Saline | 601 |
Landmark mortality 90-days after randomization (NCT02467621)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 510 |
| Normal Saline | 499 |
Number of participants with one or more episodes of clinically important GI bleeding in the ICU (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 41 |
| Normal Saline | 69 |
Composite outcome of the number of participants with one or more of the mentioned conditions in the ICU (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 360 |
| Normal Saline | 372 |
Number of participants with one or more episodes of pneumonia or clostridium difficile infection in the ICU (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 276 |
| Normal Saline | 279 |
Serious adverse reactions are: anaphylactic reactions, agranulocytosis, pancytopenia, acute hepatic failure, Steven Johnsons Syndrome and toxic epidermal necrolysis, interstitial nephritis and angioedema. (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 0 |
| Normal Saline | 0 |
Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy (NCT02467621)
Timeframe: Within 90 days
| Intervention | percentage of days (Number) |
|---|---|
| Proton Pump Inhibitor (PPI) | 92 |
| Normal Saline | 92 |
1 review available for pantoprazole and Critical Illness
| Article | Year |
|---|---|
Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Critical Illness; Gastric Mucosa; Gastroint | 2002 |
9 trials available for pantoprazole and Critical Illness
| Article | Year |
|---|---|
Proton pump inhibitors in critically ill mechanically ventilated patients with COVID-19: protocol for a substudy of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial.
Topics: Cohort Studies; COVID-19; Critical Illness; Gastrointestinal Hemorrhage; Humans; Pantoprazole; Proto | 2023 |
REVISE: re-evaluating the inhibition of stress erosions in the ICU-statistical analysis plan for a randomized trial.
Topics: Adolescent; Critical Illness; Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazol | 2023 |
Effects of oral/enteral nutrition alone versus plus pantoprazole on gastrointestinal bleeding in critically ill patients with low risk factor: a multicenter, randomized controlled trial
Topics: Aged; Anti-Ulcer Agents; Critical Care; Critical Illness; Enteral Nutrition; Female; Gastrointestina | 2020 |
Withholding Pantoprazole for Stress Ulcer Prophylaxis in Critically Ill Patients: A Pilot Randomized Clinical Trial and Meta-Analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clostridium Infections; Critical Illness; Doub | 2017 |
Stress ulcer prophylaxis in the intensive care unit trial: detailed statistical analysis plan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Care; Critical Illness; Data Interpretation, Stati | 2017 |
Enteral nutrition as stress ulcer prophylaxis in critically ill patients: A randomized controlled exploratory study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Aged; Anti-Ulcer Agents; Critical Illness; D | 2018 |
Clopidogrel in Critically Ill Patients.
Topics: Activation, Metabolic; Aged; Austria; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidog | 2018 |
Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU.
Topics: Aged; Critical Illness; Female; Gastrointestinal Hemorrhage; Humans; Injections, Intravenous; Intens | 2018 |
Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Critical Illness; Double-Blind Method; Esomepr | 2008 |
6 other studies available for pantoprazole and Critical Illness
| Article | Year |
|---|---|
The Impact of Continuous Infusion Compared to Intravenous Bolus Administration of Pantoprazole on Length of Intensive Care Unit Stay in Critically Ill Patients.
Topics: Adult; Critical Illness; Gastrointestinal Hemorrhage; Humans; Infusions, Intravenous; Intensive Care | 2023 |
BUDGET IMPACT ANALYSIS OF USING OMEPRAZOLE IMMEDIATE-RELEASE ORAL SUSPENSION IN REPLACE OF INTRAVENOUS PANTOPRAZOLE IN CRITICALLY ILL PATIENTS.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Critical Illness; Drug Costs; Humans; | 2015 |
Stress Ulcer Prophylaxis-Friend or Foe?
Topics: Critical Illness; Humans; Pantoprazole; Peptic Ulcer; Pilot Projects; Ulcer | 2017 |
Pantoprazole prophylaxis in ICU patients with high severity of disease: a post hoc analysis of the placebo-controlled SUP-ICU trial.
Topics: Adult; Critical Illness; Female; Humans; Intensive Care Units; Male; Middle Aged; Mortality; Pantopr | 2019 |
Famotidine versus pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Illness; Famotidine; Histamine H2 Antagonists; Hum | 2008 |
Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stressed related mucosal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cimetidine; Critical Illness; Gastric Mu | 2008 |